NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

CDK4/6 Inhibitors are primarily used in the treatment of metastatic breast cancer with hormone therapy. They work by inhibiting cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression. By blocking these kinases, CDK4/6 inhibitors can help slow down the growth of hormone receptor-positive breast cancer cells.

On the other hand, SERMs (Selective Estrogen Receptor Modulators) such as tamoxifen and raloxifene are used for the prevention and treatment of breast cancer. SERDs (Selective Estrogen Receptor Degraders) like fulvestrant also target estrogen receptors, but they are not primarily used in metastatic breast cancer treatment with hormone therapy. GnRH (Gonadotropin-releasing hormone) Agonists are more commonly used in hormone-sensitive cancers such as prostate cancer and gynecological conditions like endometriosis, but they are not the primary class of drugs used in metastatic breast cancer with hormone therapy.